JAK2 and myeloproliferative neoplasm: Considering the MPN driver mutations, 2 of the 6 JAK2+ patients (33.3%) shared the JAK2 V617F between HSPCs and CECs, while neither MPL nor CALR mutations were detected in the CECs.